Same drug, different jobs: both are tirzepatide, a once-weekly injection, but Mounjaro is FDA-approved for type 2 diabetes and Zepbound for chronic weight management (plus obstructive sleep apnea in people with obesity).
The active ingredient is identical, so the side-effect profile is shared. The two brands are prescribed for different goals and are not interchangeable.
What to do
Common questions
What is the difference between Mounjaro and Zepbound?
Both are tirzepatide, a once-weekly injection from the same manufacturer - the difference is the FDA-approved use. Mounjaro is approved to control blood sugar in people with type 2 diabetes. Zepbound is approved for chronic weight management in people with obesity or who are overweight with weight-related conditions, and it also carries an approval for obstructive sleep apnea in people with obesity. Tirzepatide works on two gut-hormone receptors rather than one, which distinguishes it from semaglutide products like Ozempic and Wegovy, but within the tirzepatide family the brands share the same side-effect profile: nausea, vomiting, diarrhea, constipation, and appetite loss, typically strongest early or after a dose increase. As with the semaglutide pair, the two brands are not interchangeable prescriptions, and insurance coverage for each is decided separately. Pymander, a free AI doctor available 24/7 by text, can help you sort out which option matches your situation.